MindWalk Holdings Corp. (HYFT) stock
HYFTNasdaqPharmaceutical PreparationsFiscal year ends April 30
$0.94−0.05 (-5.27%)
Close on Nov 16, 2026Market cap $43.81MP/E –Yield –
MindWalk r&d expenses
Research and development expenses are spending on new products and technology.
MindWalk's R&D Expenses for the twelve months ending Jul 31, 2026 was C$5.30M, up 39.6% year over year. For fiscal 2026 it was C$4.93M, up 17.2% from the year before. The highest annual figure on record is C$14.10M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | C$4.93M | +17.2% |
| FY2025 | Apr 30, 2025 | C$4.21M | +12.6% |
| FY2024 | Apr 30, 2024 | C$3.74M | -73.5% |
| FY2023 | Apr 30, 2023 | C$14.10M | +84.0% |
| FY2022 | Apr 30, 2022 | C$7.66M | +288.2% |
| FY2021 | Apr 30, 2021 | C$1.97M | +342.6% |
| FY2020 | Apr 30, 2020 | C$446.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | C$1.29M | +22.5% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | C$1.57M | +90.4% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | C$1.21M | +32.8% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | C$1.23M | +21.8% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | C$1.05M | -29.6% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | C$825.00K | -13.7% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | C$914.00K | -8.7% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | C$1.01M | +20.5% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | C$1.49M | +57.2% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | C$956.00K | +4.8% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | C$1.00M | -36.0% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | C$835.00K | -83.3% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | C$947.00K | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | C$912.00K | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | C$1.56M | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | C$5.00M | – |
See a number that looks wrong?